immuno-oncology

News

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.

News

In a class first, Merck's Keytruda extends survival in cervi...

Merck & Co's Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live longer when used as alongside standard first-line drugs.

News

BioNTech takes its first cancer vaccine into phase 2

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

News

Gilead combs Shoreline for NK cell therapies in $2.3bn allia...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing

News

GSK joins anti-TIGIT push with $625m upfront iTeos deal

GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with iTeos Therapeut

News

Daiichi Sankyo claims first okay for oncolytic virus in Japa...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malig

AZ, HutchMed's savolitinib gets 1st approval in China for NS...

In a class first, Merck's Keytruda extends survival in cervi...

BioNTech takes its first cancer vaccine into phase 2

Gilead combs Shoreline for NK cell therapies in $2.3bn allia...

GSK joins anti-TIGIT push with $625m upfront iTeos deal

Daiichi Sankyo claims first okay for oncolytic virus in Japa...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks